GGrantIndex
← Search

University of Arizona Cancer Center - Cancer Center Support Grant [MICEO Administrative Supplement]

$200,000P30FY2023CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications, trials & patents

Paper 39631050Paper 39622842Paper 39612086Paper 39361227Paper 39312766Paper 39151774Paper 39100646Paper 39075233Paper 38875929Paper 38858600Paper 38826434Paper 38804255Paper 38769192Paper 38759377Paper 38729260Paper 38719743Paper 38715255Paper 38687603Paper 38658768Paper 38639990Paper 38613866Paper 38612480Paper 38474232Paper 38464045Paper 38453918Paper 38386696Paper 38386396Paper 38328594Paper 38313301Paper 38309054Paper 38291312Paper 38215755Paper 38203706Paper 38199366Paper 38164625Paper 38164604Paper 38097734Paper 38097593Paper 38096366Trial NCT07214506Trial NCT06009926Trial NCT05699603Trial NCT05237960Trial NCT05121051Trial NCT04530552Trial NCT03708055Trial NCT03602066Trial NCT03601507Trial NCT03578432Trial NCT03422536Trial NCT03402230Trial NCT03376971Trial NCT03365895Trial NCT03196180Trial NCT02581137Trial NCT02568566Trial NCT02348203Trial NCT02326805Trial NCT02123849Trial NCT01686165Trial NCT01433913Trial NCT01394211Trial NCT01385280Trial NCT01370889Trial NCT01288261Trial NCT01172028Trial NCT01097304Trial NCT01077453Trial NCT00980395Trial NCT00978718Trial NCT00900432Trial NCT00900341Trial NCT00898703Trial NCT00896935Trial NCT00892268Trial NCT00841204Trial NCT00752739Trial NCT00732498Trial NCT00721877Trial NCT00702299Trial NCT00701857Trial NCT00699907Trial NCT00619060Trial NCT00608634Trial NCT00601640Trial NCT00410618Trial NCT00373022Trial NCT00363805Trial NCT00303823Trial NCT00245024Trial NCT00091325Trial NCT00078897Trial NCT00003307Trial NCT00003082Patent 9486545Patent 9435812Patent 9415110Patent 9262824Patent 5650489Patent 5510240

Abstract

ABSTRACT An estimated 62% (37 million) of Mexican-origin (MO) adults in the U.S. are predisposed to non-alcoholic fatty liver disease (NAFLD), an emerging risk factor for hepatocellular carcinoma (HCC). This is of particular concern in the Southern Arizona U.S.-Mexico border region as liver disease and liver cancer, are among the leading causes of death for MO adults. Significant disparities in the incidence and mortality of HCC in the U.S. exist across racial/ethnic and gender groups. Specifically, HCC incidence rates are two-fold higher in Hispanic populations overall compared to non-Hispanic whites. Further, HCC is one of the most fatal cancers; the 5-year cause-specific survival for Hispanics is 19%, rendering it the 3rd leading cause of cancer death in Hispanic men and the 5th leading cause in Hispanic women. Despite MO experiencing higher rates and worse outcomes for NAFLD and HCC compared to all racial and ethnic groups and other Hispanic populations, our preliminary work suggest awareness of NAFLD is low in Southern Arizona. Therefore, there is a critical need to improve liver disease and cancer health literacy for MO adults to reduce the disparities among this high-risk population. In the absence of such tools, the prevalence, morbidity, and economic costs associated with NAFLD and HCC in this population are likely to continue rising. The proposed research will address this gap by implementing a culturally tailored, multi-channel educational communication campaign to increase knowledge and public awareness of liver disease and liver cancer risk factors in MO. To achieve this objective, we will leverage our current screening and education efforts for liver disease prevention and treatment in Southern Arizona, the University of Arizona Cancer Center (UACC) catchment area. Further, we will leverage a NAFLD awareness multi-media educational communication campaign developed in partnership with El Rio Community Health Center, a Federally Qualified Health Center, including community-based education supported by promotoras de salud (community health workers). We will (1) evaluate the effectiveness of a culturally tailored, multi-channel educational communication campaign to improve knowledge and public awareness of liver disease and liver cancer risk factors in MO communities in Southern Arizona; and (2) determine the impact of promotora-led outreach, engagement, and education for cancer prevention and treatment in community-based settings. The proposed project will provide much needed evidence to inform the Community Preventive Services Task Force recommendations for engaging promotoras to increase knowledge and public awareness of liver disease and liver cancer risk factors in MO, particularly for this high-risk, underserved population.

View original record on NIH RePORTER →